

10000389

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1613sxw

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	Feb 24	PCTGEN now available on STN
NEWS	4	Feb 24	TEMA now available on STN
NEWS	5	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS	6	Feb 26	PCTFULL now contains images
NEWS	7	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS	8	Mar 24	PATDPAFULL now available on STN
NEWS	9	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS	10	Apr 11	Display formats in DGENE enhanced
NEWS	11	Apr 14	MEDLINE Reload
NEWS	12	Apr 17	Polymer searching in REGISTRY enhanced
NEWS	13	Jun 13	Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS	14	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS	15	Apr 28	RDISCLOSURE now available on STN
NEWS	16	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS	17	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS	18	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS	19	May 19	Simultaneous left and right truncation added to WSCA
NEWS	20	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS	21	Jun 06	Simultaneous left and right truncation added to CBNB
NEWS	22	Jun 06	PASCAL enhanced with additional data
NEWS	23	Jun 20	2003 edition of the FSTA Thesaurus is now available
NEWS	24	Jun 25	HSDB has been reloaded
NEWS	25	Jul 16	Data from 1960-1976 added to RDISCLOSURE
NEWS	26	Jul 21	Identification of STN records implemented
NEWS	27	Jul 21	Polymer class term count added to REGISTRY
NEWS	28	Jul 22	INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available
NEWS EXPRESS			April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

10000389

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:38:46 ON 22 JUL 2003

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 13:38:54 ON 22 JUL 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 JUL 2003 HIGHEST RN 552272-14-7

DICTIONARY FILE UPDATES: 21 JUL 2003 HIGHEST RN 552272-14-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>

Uploading 10000389c.str


L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR

10000389



G1 H,Ak
G2 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss sam
SAMPLE SEARCH INITIATED 13:39:11 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 14 TO ITERATE
```

100.0% PROCESSED 14 ITERATIONS 4 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 56 TO 504
PROJECTED ANSWERS: 4 TO 200

L2 4 SEA SSS SAM L1

```
=> s l1 full
FULL SEARCH INITIATED 13:39:16 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 254 TO ITERATE
```

100.0% PROCESSED 254 ITERATIONS 69 ANSWERS
SEARCH TIME: 00.00.01

L3 69 SEA SSS FUL L1

```
=> fil caplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST
```

SINCE FILE	TOTAL
ENTRY	SESSION
148.15	148.36

10000389

FILE 'CAPLUS' ENTERED AT 13:39:19 ON 22 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Jul 2003 VOL 139 ISS 4
FILE LAST UPDATED: 21 Jul 2003 (20030721/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.


=> s l3 full
L4 4 L3

=> d l4 1-4 ibib abs hitstr

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:15497 CAPLUS
DOCUMENT NUMBER: 138:78430
TITLE: Pharmaceutical compositions containing heterocyclic compounds as .alpha.1.beta.2 integrin-mediated adhesion inhibitors for treatment of inflammatory diseases
INVENTOR(S): Sircar, Ila; Furth, Paul; Teegarden, Bradley R.; Morningstar, Marshall; Smith, Nicholas; Griffith, Ronald C.
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokyo Koho, 72 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003002834	A2	20030108	JP 2002-117406	20020419
PRIORITY APPLN. INFO.:			JP 2001-121235	A 20010419
OTHER SOURCE(S):	MARPAT 138:78430			
GI				

10000389



AB Title compns., useful for treatment of asthma, thrombosis, arteriosclerosis, osteoporosis, tumor, rheumatoid arthritis, etc., contain heterocyclic compds. I [A = :CZ1, :N; B = CR1R2, CH:CH, S, SO, SO2, O, NR3, NR3CO, etc.; K = CH2, CHOH, CO, CF2, M = bond, (CH2)p, CO, NH, W = :Q, CHR1C:Q, C:QCHR6; X, Y = H, halo, NO2, CN, C1-6 alkylthio, (un)substituted aryl, etc.; Z, Z1 = H, OH, halo, NO2, CF3, C1-6 alkoxy, etc.; P, Q = O, S; R = (un)substituted (hetero)aryl; R1, R2 = H, halo, OR3, NR3R6, O2CNR32, N3, (un)substituted aryl, etc.; R1R2 may be linked to form O, etc.; R3 = H, (un)substituted C1-6 alkyl, (un)substituted (hetero)aryl, etc.; R6 = H, (un)substituted C1-6 alkyl; m = 0-3; n = 0-2, o, p = 1, 2] or their pharmacol. acceptable salts as active ingredients. Thus, (5R,7S)-5-[4-(trifluoromethoxy)benzyl]-3-(2,6-dichloro-4-pyridyl)-7-acetamido-1,3-diazabicyclo[3.3.0]octane-2,4-dione inhibited adhesion of Jurkat cell to ICAM-1 with IC50 value of 0.005 .mu.M.

IT 336812-89-6P 336812-90-9P 336812-91-0P
336812-92-1P 336812-93-2P 336816-67-2P
336816-69-4P 336816-73-0P 336816-77-4P
336816-81-0P 336817-14-2P 336817-20-0P
481704-12-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of heterocyclic compds. as .alpha.1.beta.2 integrin-mediated adhesion inhibitors for treatment of inflammatory diseases)

RN 336812-89-6 CAPLUS

CN Benzamide, N-[(6R,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




10000389

RN 336812-90-9 CAPLUS

CN Benzoic acid, 4-[[[(6R,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336812-91-0 CAPLUS

CN Benzamide, N-[[[(6R,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336812-92-1 CAPLUS

CN Benzoic acid, 4-[[[(6R,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 336812-93-2 CAPLUS

CN Benzoic acid, 4-[[[(6R,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336816-67-2 CAPLUS

CN Cyclopropanecarboxamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 336816-69-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336816-73-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]-5-oxo-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 336816-77-4 CAPLUS

CN 1-Piperazinebutanamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]-4-methyl-.gamma.-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336816-81-0 CAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 336817-14-2 CAPLUS

CN Morpholine, 4-[[[(6R,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]carbonyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336817-20-0 CAPLUS

CN Morpholine, 4-[[[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]carbonyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 481704-12-5 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-6-[(6-methyl-3-pyridinyl)carbonyl]-7a-[[4-(trifluoromethoxy)phenyl]methyl]-, (6S,7aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:428909 CAPLUS

DOCUMENT NUMBER: 137:6181

TITLE: Preparation of fused hydantoins as antiinflammatories.

INVENTOR(S): Iwanowicz, Edwin J.; Dhar, Murali T. G.; Launay, Michele; Potin, Dominique; Maillet, Magali Jeannine Blandine; Nicolai, Eric Antoine

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA; CEREP SA

SOURCE: PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

10000389

WO 2002044181 A1 20020606 WO 2001-US45540 20011130
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 200227128200 A5 20020611 AU 2002-27128 20011130
US 2002143035 A1 20021003 US 2001-389 20011130
PRIORITY APPLN. INFO.: US 2000-250486P P 20001201
US 2000-250653P P 20001201
US 2001-272165P P 20010228
WO 2001-US45540 W 20011130
OTHER SOURCE(S): MARPAT 137:6181
GI



AB Title compds. [I; L, K = O, S; M = N, CH; Y = CH, N; Z = H, (substituted) alkyl; T = N, CH, CR3; R1 = QX; X = (hetero)aryl; Q = bond, O, NR10, S, CO, CO2, NR10CO, NR10CO2, (substituted) alkylene, alkenylene, bivalent alkoxy, alkylthio, alkylamino, aminoalkyl, alkylsulfonyl, alkylsulfonamide, acyl, alkoxycarbonyl; R1R3 = fused carbocyclyl, heterocyclyl; R3 = halo, (substituted) alkyl, alkenyl, alkynyl, NO2, cyano, OR8, NR8R9, CO2R8, COR8, CONR8R9, NR8COR9, NR8CO2R9, OC(O)R8, OC(O)NR8R9, SR8, SOqR8a, NR8SO2Rg, SO2NR5Rq, aryl, heteroaryl, heterocyclo, cycloalkyl, O; 2 adjacent R3 form a (substituted) carbocyclic or heterocyclic fused ring; R4a, R4b = H, halo, (substituted) alkyl, alkenyl, alkynyl, NO2, cyano, OH, alkoxy, alkoxy, PhO, PhCH2O, CO2H, CHO, amino, CO2A, COA, alkylthio; A = alkyl; R8, R9 = H, (substituted) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heteroaryl, heterocyclyl; R8R9 = atoms to form a heterocyclic ring; R8a = (substituted) alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo; R10 = H, (substituted) alkyl; Q1 = (CH2)s; Q2 = (CH2)r; n, s = 0, 1, 2; q = 1, 2, 3; r = 1, 2; with provisos], were prepd. as inhibitors of leukointegrin/ICAM assocd. conditions (no data). Thus, a mixt. of (7aS,6R)-2-(3,5-dichlorophenyl)-6-hydroxytetrahydropyrrolo[1,2-c]imidazole-1,3-dione (prepn. given), Ph3P, and 4-bromophenol in THF at 0.degree. was treated with diisopropyl azodicarboxylate (DIAD) in THF followed by warming to room temp. overnight to give (7aS,6S)-2-(3,5-dichlorophenyl)-6-(4-bromophenoxy)tetrahydropyrrolo[1,2-c]imidazole-1,3-dione.
IT 433289-16-8P, (7AS,6S)-2-(3,5-dichlorophenyl)-6-(4-bromophenoxy)tetrahydropyrrolo[1,2-c]imidazole-1,3-dione
433289-20-4P 433289-21-5P 433289-22-6P
433289-25-9P, (7AS,6S)-2-(3,5-dichlorophenyl)-6-(4-

10000389

bromobenzoyloxy)tetrahydropyrrolo[1,2-c]imidazole-1,3-dione

433289-27-1P, (6S,7aS)-6-(4-bromobenzoyloxy)-2-(3,5-dichlorophenyl)tetrahydropyrrolo[1,2-c]imidazole-1,3-dione

433289-28-2P 433289-29-3P 433289-30-6P

433289-31-7P 433289-32-8P 433289-33-9P

433289-34-0P 433289-38-4P 433289-39-5P

433289-40-8P 433289-41-9P 433289-42-0P

433289-43-1P 433289-44-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of fused hydantoin s as antiinflammatories)

RN 433289-16-8 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-(4-bromophenoxy)-2-(3,5-dichlorophenyl)tetrahydro-, (6S,7aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433289-20-4 CAPLUS

CN Benzonitrile, 4-[[[(6S,7aS)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 433289-21-5 CAPLUS

CN Acetamide, N-[(4-cyanophenyl)methyl]-N-[(6S,7aS)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10000389




RN 433289-22-6 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-7a(5H)-acetic acid, 6-[(4-cyanophenyl)methoxy]-
2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-, methyl ester, (6R,7aS)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 433289-25-9 CAPLUS
CN Benzoic acid, 4-bromo-, (6S,7aS)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-
1H-pyrrolo[1,2-c]imidazol-6-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433289-27-1 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-[(4-bromophenyl)methoxy]-2-
(3,5-dichlorophenyl)tetrahydro-, (6S,7aS)-(9CI) (CA INDEX NAME)

10000389


Absolute stereochemistry.



RN 433289-28-2 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-6-(phenylmethoxy)-, (6R,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433289-29-3 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-[[4-bromophenyl)methyl]thio]-2-(3,5-dichlorophenyl)tetrahydro-, (6S,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 433289-30-6 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-[(4-bromophenyl)methoxy]-2-(3,5-dichlorophenyl)tetrahydro-, (6R,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10000389




RN 433289-31-7 CAPLUS
CN Benzonitrile, 4-[[[(6S,7aS)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 433289-32-8 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-[(3-bromophenyl)methoxy]-2-(3,5-dichlorophenyl)tetrahydro-, (6S,7aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433289-33-9 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[[[(6S,7aS)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 433289-34-0 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-6-(7-isoquinolinylmethoxy)-, (6S,7aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433289-38-4 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-[[[4-bromophenyl)methyl]methylamino]-2-(3,5-dichlorophenyl)tetrahydro-, (6S,7aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 433289-39-5 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-[[2-(4-bromophenyl)ethyl]amino]-2-(3,5-dichlorophenyl)tetrahydro-, (6S,7aS)-(9CI) (CA INDEX NAME)

10000389


Absolute stereochemistry.



RN 433289-40-8 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-[[3-(4-bromophenyl)propyl]amino]-2-(3,5-dichlorophenyl)tetrahydro-, (6S,7aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433289-41-9 CAPLUS

CN Benzonitrile, 4-[[[(6S,7aS)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]ethylamino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 433289-42-0 CAPLUS

CN Benzonitrile, 4-[[[(6S,7aS)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]propylamino]methyl]- (9CI) (CA INDEX NAME)

10000389


Absolute stereochemistry.



RN 433289-43-1 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-[(4-bromophenyl)methoxy]-2-(3,5-dichlorophenyl)tetrahydro-7a-methyl-, (6R,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433289-44-2 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-[(4-bromophenyl)methoxy]-2-(3,5-dichlorophenyl)tetrahydro-7a-(hydroxymethyl)-, (6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

19

THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10000389


L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:90045 CAPLUS
DOCUMENT NUMBER: 136:151436
TITLE: Preparation of combinatorial libraries of
N-arylsulfonyl-N-diazadioxobicyclooctyl amino acid
amides as drugs
INVENTOR(S): Lu, Shao-Po; Hebert, R. Normand
PATENT ASSIGNEE(S): Lion Bioscience A.-G., Germany
SOURCE: PCT Int. Appl., 128 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002008227	A2	20020131	WO 2001-EP8322	20010718
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1301512	A2	20030416	EP 2001-960516	20010718
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:		US 2000-621177 A 20000721 WO 2001-EP8322 W 20010718		
OTHER SOURCE(S):		MARPAT 136:151436		
AB RZN(SO2R1)CHR2CONH2 [I; R = (un)substituted Ph or CH2Ph; R1 = 2-methoxycarbonyl-3-thienyl, substituted Ph, etc.; R2 = amino acid side chain; Z = 1,3-diaza-2,4-dioxobicyclo[3.3.0]octane-3,6-diyl] were prepd. Data for antibacterial activity of I were given.				
IT 393876-35-2P 393876-37-4P 393876-39-6P 393876-44-3P 393876-46-5P 393876-47-6P 393876-54-5P 393876-55-6P 393876-56-7P 393876-57-8P 393876-61-4P 393876-62-5P 393876-65-8P 393876-67-0P 393876-68-1P 393876-72-7P 393876-75-0P 393876-76-1P 393876-79-4P 393876-80-7P 393876-81-8P 393876-82-9P 393876-83-0P 393876-84-1P 393876-85-2P 393876-89-6P 393876-90-9P 393876-91-0P 393876-92-1P 393876-93-2P 393876-94-3P 393876-95-4P 393876-96-5P 393876-97-6P 393877-00-4P RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses) (prepn. of combinatorial libraries of N-arylsulfonyl-N-diazadioxobicyclooctyl amino acid amides as drugs)				
RN 393876-35-2 CAPLUS				
CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl][(6S,7aS)-2-(3-fluorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA				

10000389

INDEX NAME)


Absolute stereochemistry.



RN 393876-37-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl][(6S,7aS)-2-(4-butoxyphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393876-39-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-1-[(4-methoxyphenyl)methyl]-2-oxoethyl][(6S,7aS)-hexahydro-1,3-dioxo-2-phenyl-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 393876-44-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-1-[(4-chlorophenyl)methyl]-2-oxoethyl] [(6S,7aS)-2-(3,4-dimethylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393876-46-5 CAPLUS

CN 1H-Imidazole-4-propanamide, .alpha.-[[[(6S,7aS)-2-(4-butylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl] [(3-fluorophenyl)sulfonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10000389




RN 393876-47-6 CAPLUS
CN Cyclohexanepropanamide, .alpha.-[[(3-fluorophenyl)sulfonyl] [(6S,7aS)-hexahydro-2-[3-(methylthio)phenyl]-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393876-54-5 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl] [(6S,7aS)-hexahydro-2-(4-methylphenyl)-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10000389



RN 393876-55-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-1-[(4-methoxyphenyl)methyl]-2-oxoethyl][(6S,7aS)-hexahydro-2-(3-methylphenyl)-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393876-56-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-1-[(4-methoxyphenyl)methyl]-2-oxoethyl][(6S,7aS)-2-(3-ethylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 393876-57-8 CAPLUS

CN 1H-Imidazole-4-propanamide, .alpha.-[[(4-bromophenyl) sulfonyl] [(6S,7aS) -2-(2,5-dichlorophenyl) hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393876-61-4 CAPLUS

CN Benzenepropanamide, .alpha.-[[(6S,7aS) -hexahydro-1,3-dioxo-2-(2,4,5-trimethylphenyl) -1H-pyrrolo[1,2-c]imidazol-6-yl] [[3-(trifluoromethyl)phenyl] sulfonyl] amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Cyclohexanepropanamide, .alpha.-[[(6S,7aS)-2-(2-ethylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl] [(3-fluorophenyl)sulfonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Chemical structure of compound 10: A 1,3,5-triazine derivative with a 4-ethylphenyl group at position 2, a 4-fluorophenyl group at position 4, and a 1-((S)-1-((cyclohexylmethyl)amino)-1-oxo-2-((4-fluorophenyl)sulfonyl)ethyl)ethyl group at position 6. The triazine ring has a hydrogen at position 7.

CN 1H-Imidazole-4-propanamide, .alpha.-[[(4-bromophenyl)sulfonyl] [(6S,7aS)-2-(3-ethylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Page 26


10000389



RN 393876-67-0 CAPLUS

CN 1H-Imidazole-4-propanamide, .alpha.-[[(6S,7aS)-2-(4-butoxyphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]] [(5-chloro-3-methylbenzo[b]thien-2-yl)sulfonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393876-68-1 CAPLUS

CN Cyclohexanepropanamide, .alpha.-[[(6S,7aS)-2-(3-ethylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]] [(3-fluorophenyl)sulfonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 393876-72-7 CAPLUS

CN Benzenepropanamide, 4-chloro-.alpha.-[[[4-chlorophenyl)sulfonyl]][(6S,7aS)-2-(4-fluorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393876-75-0 CAPLUS

CN Cyclohexanepropanamide, .alpha.-[[[4-bromophenyl)sulfonyl]][(6S,7aS)-hexahydro-2-[3-(methylthio)phenyl]-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 393876-76-1 CAPLUS

CN 1H-Imidazole-4-propanamide, .alpha.-[[(6S,7aS)-2-(4-butylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl] [(4-fluorophenyl)sulfonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393876-79-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-1-[(4-methoxyphenyl)methyl]-2-oxoethyl] [(6S,7aS)-2-(2,4-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 393876-80-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl][(6S,7aS)-hexahydro-2-[3-(methylthio)phenyl]-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-81-8 CAPLUS

CN Benzenepropanamide, .alpha.-[[[(6S,7aS)-2-(3-fluorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl](2-thienylsulfonyl)amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10000389

RN 393876-82-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-1-[(4-methoxyphenyl)methyl]-2-oxoethyl][(6S,7aS)-2-(2-fluorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-83-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-1-[(4-methoxyphenyl)methyl]-2-oxoethyl][(6S,7aS)-2-(3-chlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393876-84-1 CAPLUS

CN 1H-Imidazole-4-propanamide, .alpha.-[[[(4-bromophenyl)sulfonyl][(6S,7aS)-2-(2,4-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 393876-85-2 CAPLUS

CN 1H-Imidazole-4-propanamide, .alpha.-[[(6S,7aS)-2-(4-butylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl] (2-thienylsulfonyl)amino] -, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393876-89-6 CAPLUS

CN Cyclohexanepropanamide, .alpha.-[[(6S,7aS)-2-(3,5-dimethylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl] [(3-fluorophenyl)sulfonyl]amino] -, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 393876-90-9 CAPLUS

CN Benzenepropanamide, .alpha.-[[[(6S,7aS)-2-(5-fluoro-2-methylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]][[4-(trifluoromethyl)phenyl]sulfonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393876-91-0 CAPLUS

CN Benzenepropanamide, .alpha.-[[[(6S,7aS)-2-(2,4-dimethylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]][[4-(trifluoromethyl)phenyl]sulfonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 393876-92-1 CAPLUS

CN Cyclohexanepropanamide, .alpha.-[[(6S,7aS)-2-(2,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][(3-fluorophenyl)sulfonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393876-93-2 CAPLUS

CN Benzenepropanamide, .alpha.-[[(6S,7aS)-2-[4-(dimethylamino)phenyl]hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][(4-(trifluoromethyl)phenyl)sulfonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 393876-94-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-1-[(4-methoxyphenyl)methyl]-2-oxoethyl][(6S,7aS)-hexahydro-2-[4-(1-methylethyl)phenyl]-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393876-95-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-1-[(4-methoxyphenyl)methyl]-2-oxoethyl][(6S,7aS)-2-(2,6-difluorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 393876-96-5 CAPLUS

CN 1H-Imidazole-4-propanamide, .alpha.-[[[(6S,7aS)-2-(4-butylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][(3,4-difluorophenyl)sulfonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393876-97-6 CAPLUS

CN 1H-Imidazole-4-propanamide, .alpha.-[[[(4-bromophenyl)sulfonyl][(6S,7aS)-2-(4-butylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10000389



RN 393877-00-4 CAPLUS
CN Cyclohexanepropanamide, .alpha.-[[(3-fluorophenyl)sulfonyl] [(6S,7aS)-hexahydro-2-[2-methyl-6-(1-methylethyl)phenyl]-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:319894 CAPLUS
DOCUMENT NUMBER: 134:326532
TITLE: Preparation of 3-(hetero)aryl-1,3-diazabicyclo[3.3.0]octane-2,4-diones and analogs as inhibitors of .alpha.1.beta.2 mediated cell adhesion
INVENTOR(S): Sircar, Ila; Furth, Paul; Teegarden, Bradley R.; Morningstar, Marshall; Smith, Nicholas; Griffith, Ronald C.
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: PCT Int. Appl., 195 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

10000389

 WO 2001030781 A2 20010503 WO 2000-US29273 20001019
 WO 2001030781 A3 20011122
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
 YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 BR 2000014651 A 20020618 BR 2000-14651 20001019
 JP 2003512468 T2 20030402 JP 2001-533134 20001019
 EP 1307455 A2 20030507 EP 2000-976625 20001019
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL
 PRIORITY APPLN. INFO.: US 1999-160629P P 19991020
 US 2000-209847P P 20000607
 WO 2000-US29273 W 20001019
 OTHER SOURCE(S): MARPAT 134:326532
 GI



AB Title compds. (I) [wherein A = :CZ1 or :N; B = CH:CH, S, SO, SO₂, O, or (un)substituted N or CH₂; K = CH₂, CHOH, CO, or CF₂, M = a bond, (CH₂)_p, CO, or NH; W = CQ, CR₆C(:Q), or C(:Q)CR₆; X and Y = independently H, halo, NO₂, CN, alkylthio, (halo)alkyl, alkoxy, acyl, or (un)substituted amino or (hetero)aryl; Z and Z1 = independently H, OH, halo, NO₂, CF₃, acyl, (un)substituted amino, carbamoyl, or alkoxy; P and Q = independently O or S; R = (un)substituted (hetero)aryl; R₆ = H or (un)substituted alkyl; m = 0-3; n = 0-2; p and q = independently 1 or 2; or a pharmaceutically acceptable salt thereof] were prepd. as inhibitors of .alpha.1.beta.2 mediated cell adhesion. For example, 4-bromobenzyl bromide was added to N-(tert-butoxycarbonyl)proline Me ester in THF, the proline deprotected using TFA, 3,5-dichlorophenyl isocyanate added in the presence of DIEA in THF, and the dichlorophenylcarbamoyl deriv. cyclized using NaOEt in EtOH to afford II. In the Jurkat/ICAM-1 adhesion assay, I gave IC₅₀ values from low nM to .mu.M. I are useful in the treatment of a variety of inflammatory diseases, including psoriasis, rheumatoid arthritis, inflammatory bowel diseases, systemic lupus erythematosus, atopic dermatitis, Sjogren's Syndrome, rejection after transplantation, and graft vs. host disease (no data).

IT 336812-89-6P 336812-90-9P 336812-91-0P

10000389


336812-92-1P 336812-93-2P 336816-67-2P
336816-69-4P 336816-71-8P 336816-73-0P
336816-77-4P 336816-81-0P 336817-14-2P
336817-20-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 3-(hetero)aryl-1,3-diazabicyclo[3.3.0]octane-2,4-diones and analogs as inhibitors of .alpha.1.beta.2 mediated cell adhesion by cyclization and reaction of N-[(hetero)arylcarbonyl]proline derivs.)

RN 336812-89-6 CAPLUS

CN Benzamide, N-[(6R,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 336812-90-9 CAPLUS

CN Benzoic acid, 4-[[[(6R,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336812-91-0 CAPLUS

10000389

CN Benzamide, N-[(6R,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336812-92-1 CAPLUS

CN Benzoic acid, 4-[[[(6R,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336812-93-2 CAPLUS

CN Benzoic acid, 4-[[[(6R,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 336816-67-2 CAPLUS

CN Cyclopropanecarboxamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336816-69-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 336816-71-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336816-73-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]-5-oxo-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 336816-77-4 CAPLUS

CN 1-Piperazinebutanamide, N-[(6S, 7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]-4-methyl-.gamma.-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336816-81-0 CAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(6S, 7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10000389



RN 336817-14-2 CAPLUS

CN Morpholine, 4-[[[(6R,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]carbonyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 336817-20-0 CAPLUS

CN Morpholine, 4-[[[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]carbonyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

